Spots Global Cancer Trial Database for onartuzumab
Every month we try and update this database with for onartuzumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma | NCT01632228 | Glioblastoma | Bevacizumab Onartuzumab Placebo | 18 Years - | Hoffmann-La Roche | |
| A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma | NCT01897038 | Carcinoma, Hepa... | Onartuzumab Sorafenib | 18 Years - | Hoffmann-La Roche | |
| A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma | NCT01897038 | Carcinoma, Hepa... | Onartuzumab Sorafenib | 18 Years - | Hoffmann-La Roche | |
| A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma | NCT01632228 | Glioblastoma | Bevacizumab Onartuzumab Placebo | 18 Years - | Hoffmann-La Roche | |
| A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma | NCT01897038 | Carcinoma, Hepa... | Onartuzumab Sorafenib | 18 Years - | Hoffmann-La Roche | |
| An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study | NCT02488330 | Solid Tumor | Onartuzumab Bevacizumab Erlotinib | 18 Years - | Hoffmann-La Roche | |
| Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients | NCT01974258 | Neoplasms | Cobimetinib Cobimetinib Onartuzumab Vemurafenib | 18 Years - | Hoffmann-La Roche | |
| A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer | NCT01662869 | Gastric Cancer | 5-Fluoruracil Folinic acid Onartuzumab Oxaliplatin Placebo | 18 Years - | Hoffmann-La Roche | |
| An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study | NCT02488330 | Solid Tumor | Onartuzumab Bevacizumab Erlotinib | 18 Years - | Hoffmann-La Roche | |
| Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT) | NCT02044601 | Lung Cancer | Onartuzumab Erlotinib Paclitaxel Carboplatin Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT) | NCT02044601 | Lung Cancer | Onartuzumab Erlotinib Paclitaxel Carboplatin Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients | NCT01974258 | Neoplasms | Cobimetinib Cobimetinib Onartuzumab Vemurafenib | 18 Years - | Hoffmann-La Roche | |
| Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT) | NCT02044601 | Lung Cancer | Onartuzumab Erlotinib Paclitaxel Carboplatin Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer | NCT01662869 | Gastric Cancer | 5-Fluoruracil Folinic acid Onartuzumab Oxaliplatin Placebo | 18 Years - | Hoffmann-La Roche | |
| A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer | NCT01662869 | Gastric Cancer | 5-Fluoruracil Folinic acid Onartuzumab Oxaliplatin Placebo | 18 Years - | Hoffmann-La Roche |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
